

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1-123. (Cancelled)

124. (New) A method of treating a Reelin deficiency or dysfunction in a patient, comprising:

obtaining a biological sample from a patient diagnosed with or suspected of suffering from schizophrenia;

detecting the amount of Reelin in the biological sample;

comparing the amount of Reelin in the biological sample with the amount of Reelin in a control sample;

administering a therapeutically-effective amount of an ester of DHA to the patient to compensate for the effects of Reelin deficiency or dysfunction in the patient.

125. (New) The method of Claim 124, wherein the ester of DHA is administered in a dosage of between 0.2 grams/day and 1 gram/day.

126. (New) The method of Claim 124, wherein the ester of DHA is administered in a dosage of about 0.2 grams/day.

127. (New) The method of Claim 124, wherein the ester of DHA is administered in a dosage of about 1 gram/day.

128. (New) The method of Claim 124, wherein the administration of the ester of DHA continues for a period of 6-8 months.

129. (New) The method of Claim 124, wherein the ester of DHA is administered orally as at least one of an infant food and a dietary supplement.

130. (New) The method of Claim 124, wherein the ester of DHA is administered orally in a composition comprising a DHA content of at least 70%.

131. (New) The method of Claim 124, wherein the ester of DHA is administered orally in a capsule comprising an oil comprising an ester of DHA having a content of at least 70% DHA.

132. (New) The method of Claim 124, further comprising:

- obtaining a second biological sample from the patient;
- detecting the amount of Reelin in the second biological sample;
- comparing the amount of Reelin in the second biological sample with the amount of Reelin in at least one of a control sample and the first biological sample;
- administering a second therapeutically-effective amount of an ester of DHA to the patient to compensate for the effects of Reelin deficiency or dysfunction in the patient.

133. (New) The method of Claim 132, wherein the second biological sample is obtained about 2 months after the first biological sample is obtained.

134. (New) The method of Claim 132, wherein the second biological sample is obtained about 6 months after the first biological sample is obtained.

135. (New) The method of Claim 132, wherein the second biological sample is obtained about 8 months after the first biological sample is obtained.

136. (New) The method of Claim 132, wherein the second therapeutically-effective amount of an ester of DHA is greater than the therapeutically-effective amount of an ester of DHA administered to the patient to compensate for the effects of Reelin deficiency or dysfunction in the patient.